<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171949</url>
  </required_header>
  <id_info>
    <org_study_id>PCL 03/13</org_study_id>
    <nct_id>NCT02171949</nct_id>
  </id_info>
  <brief_title>Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases</brief_title>
  <official_title>Randomized, Open and Controlled Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Sao Rafael</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Sao Rafael</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of multiple infusions of&#xD;
      mononuclear bone marrow cells in patients with chronic liver diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a safety/efficacy phase II, open, randomized, controlled clinical trial, with two&#xD;
      arms. The study population will consist of 30 patients with chronic decompensated liver&#xD;
      disease (Child-Pugh B or C). The candidates included in the study will be asked to&#xD;
      voluntarily participate and sign the written consent.&#xD;
&#xD;
      The patients will be allocated randomly into 2 groups: in group A, the patients will undergo&#xD;
      the intervention; and in group B, the patients will be the controls. Patients of both groups&#xD;
      will receive clinical follow-up. They will be maintained on drug therapy commonly used in&#xD;
      patients with cirrhosis, which may include: spironolactone, furosemide, lactulose,&#xD;
      metronidazole, neomycin, analogs of nucleoside / nucleotide in patients with hepatitis B, and&#xD;
      vitamin complexes.&#xD;
&#xD;
      All patients included in Group A will undergo cell therapy according to the technique&#xD;
      described as follows: on day 1 (D-1), patients will be hospitalized to undergo the bone&#xD;
      marrow puncture through the iliac crest. 150 to 200 ml of bone marrow aspirate will be&#xD;
      collected. The procedure will be done under local anesthesia and sedation. The fraction of&#xD;
      mononuclear cells will be isolated from the aspirated marrow by the SEPAX (System of cell&#xD;
      processing) - Biosafe, Switzerland.&#xD;
&#xD;
      The enriched fraction of collected mononuclear cells will be resuspended in saline. The&#xD;
      obtained cell populations will be analyzed by flow cytometry for its characterization, and&#xD;
      then diluted in 20 ml saline. The cells will be injected 3 times throughout the study, on&#xD;
      days 1 (D-1), 30 (D-30) and 60 (D-60).&#xD;
&#xD;
      Patients will undergo a series of clinical and laboratory evaluations and will also be&#xD;
      submitted to the following procedures:&#xD;
&#xD;
        -  Cell blood count&#xD;
&#xD;
        -  Biochemical analysis (measurement of electrolytes - sodium and potassium)&#xD;
&#xD;
        -  Renal function tests (urea and creatinine)&#xD;
&#xD;
        -  Liver profile tests (total proteins and fractions, bilirubin, prothrombin time,&#xD;
           transaminases, alkaline phosphatase, gamma-GT)&#xD;
&#xD;
        -  Metabolic profile (glucose, total cholesterol and fractions, triglycerides)&#xD;
&#xD;
        -  Thyroid profile tests&#xD;
&#xD;
        -  Serology required for blood transfusion and bone marrow transplant in Brazil&#xD;
&#xD;
        -  Alpha-fetoprotein&#xD;
&#xD;
        -  Beta-HCG (human chorionic gonadotropin), for women&#xD;
&#xD;
        -  Handgrip dynamometer&#xD;
&#xD;
        -  Treadmill test&#xD;
&#xD;
        -  Six-minute walk test&#xD;
&#xD;
        -  Abdomen doppler ultrasound&#xD;
&#xD;
        -  Magnetic resonance imaging of the upper abdomen with elastography&#xD;
&#xD;
        -  Measurement of serum factors&#xD;
&#xD;
        -  Shear wave elastography&#xD;
&#xD;
      Also, the patients will respond to questions from the SF (Short Form) -36 questionnaire (for&#xD;
      assessment of quality of life).&#xD;
&#xD;
      Clinical follow-up will be kept for patients who suspend their participation in the study for&#xD;
      any adverse event and / or laboratory abnormality, or for the patient's own desire, following&#xD;
      insurance protocols. In addition to the clinical and surgical follow-up, specific medical&#xD;
      care will be offered to patients who experience adverse events, until stabilization of the&#xD;
      patient, even if the target date for completion of the study has been exceeded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Child-Pugh score</measure>
    <time_frame>12 months</time_frame>
    <description>Functional class improvement of 2 points on Child-Pugh score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of MELD score</measure>
    <time_frame>12 months</time_frame>
    <description>Functional class improvement of 2 points on MELD score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of muscle strength</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in the degree of muscle strength assessed using handgrip dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic fibrosis</measure>
    <time_frame>12 months</time_frame>
    <description>Decrease of hepatic fibrosis detected by elastography shear waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement on the SF-36 questionnaire score, which evaluates quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of functional capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in the functional capacity, assessed by six-minute walk test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum bilirubin levels</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in the serum bilirubin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum albumin levels</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in the serum albumin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of prothrombin time</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in prothrombin time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum levels of cytokines</measure>
    <time_frame>12 months</time_frame>
    <description>Decrease in the serum levels of cytokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of fibrosis markers levels</measure>
    <time_frame>12 months</time_frame>
    <description>Decrease in the serum levels of fibrosis markers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Hepatitis</condition>
  <condition>Hepatic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone marrow mononuclear cell therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infusion of bone marrow mononuclear cells.</intervention_name>
    <description>Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.</description>
    <arm_group_label>Bone marrow mononuclear cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of liver cirrhosis of different etiologies, confirmed by clinical&#xD;
             examination, laboratory tests, imaging studies and / or biopsy that shows process of&#xD;
             evolution to cirrhosis or established cirrhosis (equivalent to Metavir score F3/F4);&#xD;
&#xD;
          -  Non-participation on the waiting list for liver transplantation or, in case of&#xD;
             participation, allocation after the fifth position in the list, for subjects with&#xD;
             blood group A or O, and after the third position for subjects with other blood groups;&#xD;
&#xD;
          -  Absence of clinical, laboratory and radiological evidence of hepatocellular carcinoma;&#xD;
&#xD;
          -  Absence of pregnancy potential or negative pregnancy test for female patients, or&#xD;
             impossibility to use a contraception method during the study;&#xD;
&#xD;
          -  Permission for doing the puncture of iliac crest after evaluation of pre-anesthetic&#xD;
             visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossibility to obtain vascular access for percutaneous procedure;&#xD;
&#xD;
          -  Sepsis;&#xD;
&#xD;
          -  Hepatic encephalopathy detected at the screening tests;&#xD;
&#xD;
          -  Budd-Chiari syndrome;&#xD;
&#xD;
          -  Severe coagulopathy with INR &gt; 2,4 or platelet count &lt; 30.000;&#xD;
&#xD;
          -  Presence of malignancies (excluding non-melanoma skin cancer);&#xD;
&#xD;
          -  Decompensated heart failure;&#xD;
&#xD;
          -  Primary hematologic diseases;&#xD;
&#xD;
          -  Renal failure with creatinin &gt; 2,5mg/dl;&#xD;
&#xD;
          -  Coinfection with HIV;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Dependence of organic medium such as circulatory or ventilatory;&#xD;
&#xD;
          -  Any other comorbidity with an impact on the survival in 2 years;&#xD;
&#xD;
          -  Participation in other clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André C Lyra, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno SF Souza, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo L Braga, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lourianne N Cavalcante, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milena BP Soares, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo R dos Santos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ticiana F Larocca, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital São Rafael</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>André C Lyra, PhD</last_name>
    <phone>557132816455</phone>
    <email>aclyra@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital São Rafael</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André C Lyra, PhD</last_name>
      <phone>55713281-6455</phone>
      <email>aclyra@live.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Sao Rafael</investigator_affiliation>
    <investigator_full_name>Ricardo Ribeiro dos Santos</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis</keyword>
  <keyword>Hepatic cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

